

1 **A prospective study of MRI biomarkers in the brain and lower limb**
2 **muscles for prediction of lower limb motor recovery following stroke.**

3 **Mat Elameer^{1,2*}, Hannah Lumley², Sarah A. Moore^{2,3}, Katie Marshall⁴, Abi Alton², Fiona E.**
4 **Smith⁵, Akif Gani⁶, Andrew Blamire⁷, Helen Rodgers¹, Christopher I. M. Price², Dipayan**
5 **Mitra^{1,2}**

6

7

8 ¹Department of Neuroradiology, Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom

9 ²Stroke Research Group, Newcastle University, Newcastle-upon-Tyne, United Kingdom

10 ³Department of Sport, Exercise and Rehabilitation, Northumbria University, Newcastle-upon-Tyne,
11 United Kingdom

12 ⁴Department of Medical Physics, Newcastle University, Newcastle-upon-Tyne, United Kingdom

13 ⁵Department of Neuroscience, Manchester Metropolitan University, Manchester, United Kingdom

14 ⁶Department of Stroke Medicine, Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom

15 ⁷Newcastle Magnetic Resonance Centre, Newcastle University, Newcastle-upon-Tyne, United
16 Kingdom

17

18

19

20 *** Correspondence:**

21 Dr. Mat Elameer

22 mathew.elameer@nhs.net

23 **Keywords: stroke, biomarkers, MRI, recovery, lower limb, strength, spectroscopy,**
24 **tractography**

25

26 **Abstract**

27 The aim of this prospective observational longitudinal study was to explore and decipher the
28 predictive value of MRI biomarkers in the brain and lower limb muscles for 3- month lower limb
29 motor recovery following stroke. In the brain, we measured the integrity of the corticospinal tract
30 (fractional anisotropy / 'FA'). In the muscles, we measured volume, fatty replacement (fat fraction
31 analysis and proton spectroscopy) and oedema. Measurements were taken at two time points: 1)
32 within 4 weeks of stroke (baseline measurement, clinical and imaging) and 2) three months following
33 stroke (follow up measurement, clinical only). Clinical measurements consisted of assessments of
34 functional ability and strength (Fugl-Meyer score, motor NIHSS, Functional Ambulation Category/
35 'FAC', and muscle dynamometry).

36 Twenty-three patients completed imaging and clinical assessments at baseline and follow-up; five
37 patients had partial imaging assessment. The results provided some evidence that damage to the
38 corticospinal tract would result in less motor recovery: recovery of the Fugl-Meyer score and
39 dynamometric ankle plantarflexion, ankle dorsiflexion, and knee extension correlated positively and
40 significantly with fractional anisotropy (0.406 – 0.457; $p = 0.034$ – $p = 0.016$). However, fractional
41 anisotropy demonstrated a negative correlation with recovery of the Functional Ambulation Category
42 (-0.359, $p = 0.046$). For the muscle imaging, significant inverse correlation was observed between
43 vastus lateralis fat fraction versus NIHSS recovery (-0.401, $p = 0.04$), and a strong positive
44 correlation was observed between ratio of intra- to extra-myocellular lipid concentrations and the
45 recovery of knee flexion (0.709, $p = 0.007$).

46 This study supports previous literature indicating a positive correlation between the integrity of the
47 corticospinal tract and motor recovery post-stroke, expanding the limited available literature
48 describing this relationship specifically for the lower limb. However, recovery of functional
49 ambulation behaved differently to other clinical recovery markers by demonstrating an inverse
50 relationship with corticospinal tract integrity. The study also introduces some muscle imaging
51 biomarkers as potentially valuable in the prediction of three month lower limb motor recovery
52 following stroke.

53

54 1 Introduction

55 There are unique challenges posed by stroke and its associated morbidity. Current estimates place
56 over one million stroke survivors in the UK, with societal costs estimated around £26 billion and
57 projected to rise to over £68 billion annually by 2035 (1). Much of the societal and personal cost of
58 stroke is due to stroke related impairments with nearly three quarters of stroke survivors report leg
59 weakness (2). Further to loss of leg power, stroke has a significant and multifactorial effect on
60 walking. Whilst approximately 85% of all people who survive a stroke can independently walk after
61 6 months, a large proportion (approximately 40%) of survivors unable to walk independently early
62 after stroke do not regain this function with time (3–5). Motor recovery following stroke usually
63 plateaus at around 3 months, with diminishing returns beyond this time (6–8).

64 It is important to understand and predict the motor recovery of stroke patients (9–11) to help
65 clinicians discuss prognosis with patients and families; to help provide individualised rehabilitation
66 (for example, focussing on recovery if likely to be successful, or on adaptation if recovery is
67 unlikely); and because research studies may be confounded by differences between study arms in
68 initial prognosis, which could be reduced by prognosis-based stratification.

69 Despite the high incidence of stroke and the significant associated disability, the ability to accurately
70 predict motor recovery following acute ischaemic stroke remains limited. Most of the literature
71 regarding prognostic biomarkers has emphasised upper rather than lower limb recovery (10–14).
72 Advanced brain imaging biomarkers (for example, imaging of function or white matter
73 microstructure) have been found promising for the prediction of upper limb recovery (15–17) which,
74 when combined with clinical markers, have the greatest prognostic accuracy (12). The exact
75 neuroanatomical location of the infarcts can have a significant impact on motor and non-motor
76 outcomes, with damage in the region of white matter tracts being a poor prognostic feature (18).
77 Although the impact of persistent lower limb deficits is also significant only a small number of
78 studies have attempted to translate these neuroimaging and clinical prognostic biomarkers to
79 investigate lower limb motor recovery (8,19–22), the most successful of which was the TWIST
80 algorithm which favours clinical markers over brain imaging biomarkers (5); however, this has yet to
81 be externally validated and internal validation (N = 93) found up to 17% of patients' recovery
82 trajectories unaccounted for by the algorithm (8).

83 Although tracts connecting the brain and muscles are bidirectional, to date, most stroke motor
84 recovery studies focus solely on the source organ (the brain). Few studies have investigated the target
85 organ (muscle) which may be as important for predicting recovery.

86 In this study we aimed to address these gaps in the literature by exploring the relationship between
87 lower limb motor recovery at three months with MRI markers of structural damage to the
88 corticospinal tract and lower limb musculature change. Our aim was to explore the possible utility of
89 advanced and novel brain and lower limb muscle MRI biomarkers to predict the recovery of stroke
90 patients.

91 Specifically, we set out to test the hypotheses that:

- 92 1) Increased damage to the corticospinal tract within four weeks of stroke measured by lower
93 fractional anisotropy (FA) or reduced whole-tract volume may result in less recovery of lower
94 limb impairment and walking ability at three months.
- 95 2) Early features of muscle oedema, atrophy, or macro/microscopic fat redistribution may be
96 detectable within four weeks after stroke and may correlate with impaired recovery of lower

97 limb power and walking ability at three months, and/or with markers of increased damage to
98 the corticospinal tract.
99 3) Combining brain and lower limb biomarkers in a regression model may result in more
100 accurate predictions of motor recovery than considering individual biomarkers alone.

101

102 **2 Methodology**

103 **2.1 Study design and setting**

104 This study was designed as a prospective observational longitudinal cohort study, consisting of two
105 study time points: the first timepoint within four weeks of stroke onset consisting of both imaging
106 and clinical measurements; and the second timepoint at three months after stroke onset consisting of
107 clinical measurements only. The study was designed so that the brain and lower limb MRI
108 assessments were performed blinded to each other and to the clinical details.

109 Recruitment started in October 2019, and the last patient completed followed up in March 2022.
110 Participants were enrolled from five stroke units across two major healthcare trusts in North East
111 England. The clinical assessments were performed within hospital, at the participant's home, or at the
112 Newcastle Magnetic Resonance Centre at Newcastle University. Research MRI scans were also
113 performed at the Newcastle Magnetic Resonance Centre.

114 **2.2 Participants**

115 For inclusion in the study, patients had to be ≥ 18 years old and within four weeks of their first ever
116 unilateral, suspected supratentorial ischaemic stroke causing a unilateral lower limb motor deficit (+/-
117 an upper limb motor deficit) as defined by a Medical Research Council (MRC) strength score at least
118 >1 and at best <5 .

119 Patients were excluded if they had: 1. An absolute contraindication to MRI (e.g. pacemaker; metal
120 implants). 2. Suspected posterior circulation or primary haemorrhagic stroke. 3. Previous history of
121 anterior circulation stroke (clinical or radiological evidence) or posterior circulation stroke with
122 residual clinical deficit. 4. A lack of capacity to provide informed consent to participate. 5. An
123 inability to answer the MRI safety questionnaire. 6. Moderate to high level of pre-stroke dependency
124 (modified Rankin Score >2). 7. Any other pre-existing comorbidity causing a significant lower limb
125 deficit. 8. Inability to transfer with the assistance of one or two people, depending on the recruitment
126 site. 9. Inability to attend the three-month follow-up assessment.

127 **2.3 Clinical assessment procedures and variables**

128 Potentially eligible participants were identified by the study PIs within each organisation (AG/SM),
129 and an appropriately trained research assistant (HL/AA) also actively screened new admissions to the
130 participating stroke units. Once identified, a two-step screening and consent process was performed
131 as approved by an NHS research ethics committee.

132 The consent and data collection procedures are detailed in **Figure 1**.

133 Baseline demographic and clinical data were recorded by the research assistant, including patient
134 demographics (age, sex; self-reported handedness), date of stroke onset, pre-morbid modified Rankin
135 score, pre-morbid walking status (independent or not), associated co-morbidities e.g. presence of

136 diabetes, hypertension, arthritis of affected limb, and stroke treatment (including
137 thrombolysis/thrombectomy). Leg dominance is complex and task specific but generally follows
138 hand dominance (23) – given the practical difficulties in objective leg dominance assessment for
139 post-onset stroke patients, we extrapolated leg dominance from self reported hand dominance.

140 Baseline and follow-up clinical assessments included measurements of lower limb impairment (Fugl-
141 Meyer Lower Extremity score (FM), lower limb motor National Institutes of Health Stroke Scale
142 (NIHSS), and hand-held dynamometry measurement), and lower limb activity (Functional
143 Ambulation Category (FAC)).

144 The Fugl-Meyer score was selected as a well validated tool to assess the volitional movement, reflex
145 activity, coordination and speed of movements around the ankle, knee, and hip (24–26). The lower
146 limb motor component of the NIHSS provides a complementary assessment of lower limb power by
147 testing the ability to raise and hold the leg against gravity (26,27). As both these scores provide
148 categorical assessments, we also included hand-held dynamometry as a continuous quantitative
149 measurement of lower limb motor strength (28) for flexion and extension of the ankle, knee, and hip,
150 in addition to abduction and adduction of the hip. The Functional Ambulation Category (FAC)
151 provides a categorical assessment of the ability to walk independently (29). Further detail can be
152 found on these clinical assessments in [Appendices 1-4](#).

153 Fugl-Meyer and NIHSS scores were reported for the affected limb, and the dynamometry was
154 normalised by calculating the ratio of values from affected:unaffected limbs to correct for any
155 baseline differences. Recovery was defined by the value of dynamometry, FAC and FM at follow-up
156 minus baseline, and baseline minus follow-up for NIHSS.

157 All assessments were performed following dedicated training and were indirectly supervised by a
158 Clinical Professor of Stroke Medicine (CP) and an Assistant Professor of Sport, Exercise, and
159 Rehabilitation (SM).

160 **2.4 Imaging assessment procedures and variables**

161 All MRI scans were performed on a Philips Intera Achieva 3T system (Philips Healthcare,
162 Amsterdam, Netherlands) at the Newcastle Magnetic Resonance Centre.

163 **2.4.1 Lower limb Imaging**

164 For MR data acquisition the body radiofrequency coil for signal transmission and surface-array coils
165 for signal transmission were used. Patients were positioned feet-first supine and lower limbs were
166 scanned bilaterally from the greater trochanter to the knee joint. The core protocol consisted of T1-
167 weighted, Short Tau Inversion Recovery (STIR), 2D, 3-point Dixon, and a single-voxel Point
168 RESolved Spectroscopy (PRESS) sequence with 96 signal averages performed at rest with voxels
169 placed in the vastus lateralis muscles bilaterally. MR acquisition details are given in [Appendix 5](#).

170 **2.4.2 Brain Imaging**

171 Whole-brain structural imaging was obtained using a volumetric T1-weighted sequence and 3mm
172 thick axial spin-echo T2 slices covering the whole brain. A 64-directional ($b=1000 \text{ s.mm}^{-2}$) diffusion
173 weighted acquisition was acquired including 6 acquisitions with no diffusion weighting, and an
174 identical non-diffusion weighted image was acquired with reversed phase encoding gradients for
175 distortion correction. The directional diffusion of water was used as a surrogate marker for white
176 matter tract mapping and integrity (30). Specifically, the fractional anisotropy (FA) and calculated

177 tract volumes were extracted as key biomarkers - we used FA because it contains information about
178 damage to white matter tracts more specifically than MD, which contains information about damage
179 to other kinds of brain parenchyma. This is because MD averages away the differentiation in
180 diffusion signal over multiple directions, as opposed to FA which specifically measures the
181 unidirectional preference of diffusion signal within a voxel. Further, we used FA rather than
182 separately describing axial and radial diffusivities (AD and RD) because it is the most complete and
183 widely reported single tractography biomarker, is sensitive to changes in stroke patients, and
184 integrates information about both axial and radial diffusivities (30,31). Further detail can be found in
185 **Appendix 5.**

186 **2.4.3 MRI and MRS data processing**

187 Leg and brain imaging were separated to prevent observer bias, and all analyses were conducted
188 blinded to the patient's clinical status. For all leg and brain MRI biomarkers, the affected side was
189 normalised against the unaffected side to account for background variability.

190 Vastus lateralis muscle quality was assessed on T1-weighted imaging using the 6-point semi
191 quantitative scale (32,33) proposed by Mercuri et al. and STIR imaging was assessed to indicate the
192 degree of macroscopic oedema using a 4-point qualitative scale (no change, mild, moderate, or severe
193 increased signal). These were both performed by two consultant diagnostic neuroradiologists (ME
194 and DM).

195 All quantitative MRI lower leg data were processed using in-house written software in Matlab
196 (MathWorks, Natick, MA, USA). Dixon data were reconstructed (34) using a six-component lipid
197 model and considering a single T2* decay. Fat fraction (FF) was calculated as:

$$198 \quad \text{Fat fraction} = \frac{SI(\text{fat})}{SI(\text{fat}) + SI(\text{water})} * 100$$

199
200 where SI = signal intensity. FF maps that included subcutaneous and bone FF values < 95%, or
201 partial fat-water swaps would have been excluded for analysis (none met this threshold for
202 exclusion). Reconstructed Dixon data is shown in **Figure 2.** A three point Dixon technique is
203 particularly robust for calculating quantitative fat maps, yet is also a fairly quick and easily
204 reproducible MRI sequence. The algorithms used rely on measuring the amount of dephasing caused
205 by chemical shift from intra-voxel fat and water mixing (the resonance frequency of protons in the fat
206 and water environments are slightly different) (35). The advantage over more specific spectroscopy
207 analysis as described below is the ability to cover much larger areas of muscle with good spatial
208 resolution within a practical time frame.

209 Regions of interest (ROIs) were drawn manually on the water image by a clinical medical physics
210 postgraduate student (KM) using the free software tool (www.itknap.org). The Vastus Lateralis
211 muscle was delineated bilaterally avoiding inclusion of other muscles, subcutaneous and
212 intermuscular fat, tendons and major blood vessels for five central slices (150mm of the muscle
213 length) centered at maximal muscle thickness. FF for an average of these segmented volumes areas
214 were calculated from the registered fat-fraction map in ITK-SNAP, as was the volume of segmented
215 contractile muscle.

216 Spectroscopy analysis was performed by an experienced MR physicist (FES). Spectroscopy can very
217 accurately delineate the concentration of molecules with distinct resonance frequencies (36), with the
218 trade-off that in order to distinguish peaks with similar resonance frequencies, a high signal to noise
219 ratio is required – which can be obtained by utilising a larger voxel size, but at the expense of spatial
220 resolution. This technique enables not only the measurement of fat concentration within muscles, but
221 also in many cases the intra- and extra-cellular lipid concentrations can be differentiated (35).
222 Spectroscopy is widely used in clinical neuroradiology practice to investigate brain tumours and
223 other diseases (36), and has been used in the research setting to investigate muscle composition
224 (35,37). Example voxel placement can be seen in [Figure 3](#). All spectra were analysed using ‘Java-
225 based magnetic resonance user interface’ software (jMRUI version 3.0;
226 <http://www.mrui.uab.es/mrui/>) and the AMARES algorithm. Signal amplitudes from intra- and
227 extramyocellular lipids (IMCL and EMCL) were separated by peak fitting ([see Figure 4](#)) and
228 quantified by comparison to the water proton signal from non-water suppressed spectra. Absolute and
229 creatine-normalised IMCL and EMCL concentrations were extracted.

230 **2.4.4 Manual CST analysis**

231 Several pre-processing steps were taken prior to analysis of the brain MRI data, which are described
232 in further detail in Appendix 5. These included conversion from DICOM to NIFTI-1 using dcm2niix,
233 followed by correction of eddy current and motion artefact in the diffusion volumes through use of
234 the FSL TOPUP/EDDY algorithm.

235 Manual segmentation of regions of interest corresponding to the location of the corticospinal tract
236 (CST) was performed bilaterally in the: corona radiata, posterior limb of internal capsule (PLIC), and
237 cerebral peduncles. The corona radiata slice was selected to be one slice above the top of the
238 ventricles; the PLIC slice was selected at the level of the foramina of Munro; and the cerebral
239 peduncle slice was selected one slice below the bottom of the thalami ([Figure 5](#)). The volumetric T1
240 scan and the colour FA maps were used as guidance to identify the corticospinal tract at these levels,
241 with reference to a detailed white matter atlas (38).

242 Descriptive statistics were calculated in DSI studio and data describing the fractional anisotropy were
243 obtained from the cross-sectional regions of interest corresponding to the tract at these three separate
244 locations. The affected side data was normalised against the unaffected side to account for any
245 background variation.

246 **2.4.5 Automated CST analysis**

247 Automatic CST analysis was performed with manual supervision in DSI Studio (39–42). An example
248 can be seen in [Figure 6](#). The whole tract volume and average FA were extracted on either side, and
249 the affected side normalised against the unaffected side. Further detail is provided in [Appendix 5](#).

250 **2.5 Statistical analysis**

251 To test the hypothesis that increased damage to the corticospinal tract measured by lower FA may
252 result in less recovery of lower limb power and walking ability after three months, we performed
253 individual correlations between all DTI-derived metrics and all clinical recovery metrics, as defined
254 in the previous section.

255 To test whether early features of muscle oedema, muscle atrophy (volume, fat fraction, and increased
256 Mercuri score) or microscopic fat redistribution (intra & extramyocellular lipid concentrations)
257 correlated with impaired recovery of lower limb power and walking ability at three months, we also

258 performed individual correlations between these MRI muscle variables and all clinical recovery
259 metrics.

260 Finally, the interaction between brain and lower limb biomarkers was determined by performing
261 correlations between each brain and lower limb biomarker.

262 Statistical analysis was performed in SPSS. Spearman's rho was calculated with 95% p-values for all
263 biomarkers to account for non-parametric and ordinal biomarkers within correlating pairs. One-sided
264 testing was performed because our hypotheses included expected directions of correlation. All MRI
265 biomarkers were also entered to a multivariate regression analysis as predictors of motor outcome at
266 3 months (lower limb Fugl-Meyer score).

267 As this was an exploratory study, an a-priori sample size calculation was not performed. When
268 patients were unable to tolerate/complete the MRI scan, participants were included in any
269 correlations for which biomarker pairs were available and automatically excluded when one or both
270 biomarkers in a pair were not available.

271 **3 Results**

272 A cohort of 44 acute ischaemic stroke patients (mean age: 57; 26 Male, 18 Female) were recruited at
273 Step 2. Due to participant attrition (reasons detailed in [Figure 7](#)) a total of 28 participants attended the
274 baseline clinical assessment and MRI scan. A summary of their demographics and baseline scoring is
275 presented in [Table 1](#). No patients required stay on an intensive care unit.

276 23 participants fully completed the baseline clinical assessment and MRI, and 5 partially completed
277 due to either claustrophobia in the scanner (N=4) or dynamometer failure (N=1). All MRI scans were
278 performed within 28 days of stroke onset (mean 17.2 days; range 2-27).

279 Of the 24 patients for whom brain MRI was completed, the infarcts were located as follows: 8
280 frontal, 4 parietal, 1 temporal, 6 basal ganglia, 6 brainstem. The brainstem infarcts were included
281 because they were all suspected to be anterior circulation infarcts at the point of recruitment. One
282 patient was excluded as they were identified as non-stroke (meningioma). 11 infarcts were localised
283 within the left hemisphere, and all except one patient were right leg dominant. The dominant leg was
284 affected clinically in 13/24 (54%) cases.

285 14/24 (58%) leg MRIs demonstrated spectra of sufficiently quality to estimate microscopic lipid
286 concentration, with 10/24 (42%) cases unable to resolve IMCL/EMCL peaks on one or both sides.

287 Two participants had significant artefacts on Dixon sequences which precluded segmentation of the
288 vastus lateralis muscles. Two further participants (BA1 and AA2) also had outlying fat fractions felt
289 to be uniform scaling errors after inspection were included because both limbs were equally affected
290 so our reported variable of affected:unaffected limb ratio would normalise the discrepancy.
291 Satisfactory quality was achieved for all other cases in the structural leg and brain imaging. Interslice
292 agreement for the diffusion data was 83% (range: 70%-86%) and all scans passed visual inspection
293 following correction with TOPUP/EDDY.

294 Due to participant attrition following the baseline clinical assessment and MRI scan (reasons detailed
295 in [Figure 5](#)) a total of 24 participants completed the follow up clinical assessment. Of these, 23
296 participants fully completed the follow up assessment and 1 partially completed due to dynamometer
297 failure.

298 **3.1 Statistical analyses**

299 **3.1.1 Does increased damage to the corticospinal tract as measured by lower FA correlate with**
300 **less recovery of lower limb motor impairment and walking ability by 3 months?**

301 We found evidence to support this hypothesis. The biomarker data is shown in **Table 2**. Clinical
302 recovery data and full results from the statistical analysis are available in the **Supplementary Data**
303 **File (Worksheets 4 and 5)**.

304 Confirmatory positive correlations were observed between centrum semiovale FA and recovery of
305 ankle plantarflexion (0.457, $p = 0.019$) and ankle dorsiflexion (0.406, $p = 0.034$). Further significant
306 correlation was identified between cerebral peduncle FA and recovery of knee extension (0.423, $p =$
307 0.032).

308 Further support for the hypothesis was found in the recovery of Fugl-Meyer score; normalised FA
309 measured in the centrum semiovale positively correlated with recovery of FM (0.457, $p = 0.016$).

310 However, we did find that the recovery of functional ambulation (FAC) contradicted our hypothesis
311 by significantly negatively correlating with whole CST FA (-0.359, $p = 0.046$).

312 **3.1.2 Do markers of increased atrophy, oedema, or microscopic fat redistribution correlate**
313 **with less recovery of lower limb motor faculty by 3 months?**

314 We found some evidence to support this hypothesis. Per participant data from the lower limb
315 biomarkers and clinical recovery metrics plus full results from the statistical analysis are available in
316 the **Supplementary Data File (Worksheets 3, 4, and 6 respectively)**.

317 We identified negative correlations between Mercuri score and recovery of hip extension (-0.386, $p =$
318 0.042), and NIHSS and vastus lateralis mean fat fraction (-0.401, $p = 0.04$).

319 We also found a negative correlation between extramyocellular lipid concentration and recovery of
320 knee flexion (-0.591, $p = 0.028$). When the ratio of intra- to extra-myocellular lipid concentrations
321 was calculated, this was found to correlate with recovery of knee flexion strongly positively (0.709, p
322 = .007).

323 However, we did again find that recovery of FAC contradicted our hypothesis by demonstrating a
324 positive correlation with vastus lateralis mean fat fraction (0.377, $p = 0.046$).

325 We also found a negative correlation between recovery of ankle dorsiflexion and vastus lateralis
326 volume (-0.456, $p = 0.022$) that was contradictory to the hypothesis.

327 **3.1.2.1 Is there any correlation between MRI markers of increased injury to the corticospinal**
328 **tract and MRI markers of oedema or fatty atrophy within the vastus lateralis (VL)**
329 **muscle?**

330 We found some evidence to support this hypothesis. The brain biomarkers are reported in **Table 2**,
331 and the lower limb biomarkers along with full results from the statistical analysis are available in the
332 **Supplementary Data File (Worksheets 3 and 7 respectively)**.

333 When the normalised brain markers were compared to the normalised leg markers, we identified
334 positive correlations between the vastus lateralis volume and FA measured at the CSO (0.426, $p =$

335 0.027), PLIC (0.599, $p = 0.002$), and CP (0.545, $p = 0.005$), in addition to the whole tract FA (0.578,
336 $p = 0.003$) and volume (0.0416, $p = 0.030$).

337 Further support was found through strong negative correlation between whole tract volume and
338 vastus lateralis fat fraction (-0.556, $p = 0.004$).

339 Extramyocellular lipid concentration was seen to positively correlate with FA measured at the CSO
340 (0.577, $p = 0.019$) and CP (0.484, $p = 0.047$) which initially seems contradictory to the hypothesis,
341 however the ratio of IMCL to EMCL demonstrated a very strong negative correlation with whole
342 tract volume (-0.797, $p = 0.001$).

343 **3.1.3 Was there any benefit to combining MRI brain and lower limb biomarkers in a model to** 344 **predict recovery?**

345 Statistical modelling utilizing regression (automatic linear modelling for dynamometry recovery
346 variables, and ordinal modelling for NIHSS / FAC / FM recovery variables) did not identify
347 statistically significant predictive benefit to combining MRI variables within our small sample size.

348 **4 Discussion**

349 Damage to the corticospinal tract measured by reduction in fractional anisotropy has been linked to
350 impaired movement following stroke in the upper limb, but there are limited studies assessing the
351 effect on lower limb. We found several significant correlations between markers of preserved CST
352 integrity and improved recovery of lower limb motor strength following stroke which support this
353 hypothesis – particularly in the dynamometry and Fugl Meyer assessments. These findings support
354 the importance of the corticospinal tract in motor control of the lower limbs and contribute to the
355 evidence supporting the use of diffusion tensor MRI methods to evaluate the integrity of these tracts.

356 Walking is however more complicated than cortical motor control and power of the lower limbs: it
357 also relies on extrapyramidal tracts such as the vestibulospinal tract and reflexes/pattern generators in
358 the spine. Descending corticospinal tract neurons can play an inhibitory role in the modulation of
359 these processes (43,44), which may provide a possible explanation for recovery of functional
360 ambulation demonstrating a significant inverse correlation with CST integrity.

361 One of the novel aspects to this study was the collection of MRI biomarkers of the structural integrity
362 of the target organ (lower limb musculature). Changes in muscle structure and function, such as
363 decreased protein synthesis, are detectable within days of a period of inactivity even in healthy adults
364 (45) and even more so in acutely unwell patients with stroke or other conditions (46,47).
365 Furthermore, changes in the number of motor units of stroke patients have been shown to be reduced
366 as early as 4 hours after stroke onset. Advances in MRI imaging of muscles have enabled
367 measurements of both macroscopic and microscopic structure to be accurately performed using
368 widely available clinical scanners (34,48). Combining muscle biomarkers with brain and clinical
369 information may improve the accuracy of prognostic models for stroke recovery, and it may also
370 provide novel insights into the neurophysiological mechanisms underlying post-stroke clinical
371 syndromes.

372 Most of our patients were scanned in the subacute period after stroke and there is some evidence to
373 suggest that at least at the microscope level there may be structural changes identified within muscle
374 in the subacute phase following insult (49–51). This provided the basis for our hypothesis that if we
375 were to see any significant relationship between lower limb MRI biomarkers and recovery post

376 stroke, they may be early changes of atrophy (smaller volume compared to baseline or contralateral
377 limb, and lipid infiltration) which may indicate an impaired degree of recovery.

378 We did find some evidence to support this hypothesis, through negative correlations between NIHSS
379 recovery and VL fat fraction, and Mercuri score with hip extension recovery. Recovery of functional
380 ambulation behaved in the opposite direction to what we expected, as it did when correlated with
381 CST integrity. The strength of correlation was generally fairly weak and not consistent for all MRI
382 and recovery biomarkers. The statistical limitations of the study are discussed below.

383 The MRI spectroscopy results were also of interest. Greater recovery of knee flexion was associated
384 with a modest reduction in EMCL, but a strong increase in the IMCL/EMCL ratio. An inverse
385 relationship was observed in the brain vs. muscle correlation – higher FAs were associated with
386 modest increase in EMCL, but a strong reduction in IMCL/EMCL ratio. These results may suggest
387 the importance of shift of lipid between the intra and extramyocellular lipid compartments post-
388 stroke, of more significance than changes in the absolute concentration of either IMCL or EMCL.
389 However, the fact that IMCL/EMCL ratio appears to reduce with higher FA yet increase with greater
390 recovery, when the literature and our results also support higher FA being associated with greater
391 recovery, is difficult to rationalise.

392 Indeed, it is important to consider the results obtained within the context of the study limitations.
393 This was an exploratory study aiming to provide a broad assessment of the interaction between
394 leg/brain MRI and clinical recovery biomarkers for stroke patients. As such we have evaluated many
395 biomarkers in a relatively small sample size. Furthermore, as it was not appropriate to transport any
396 patients with a moderate-to-severe lower limb deficit via taxi from hospital to our research scanning
397 center (NMRC) due to medical instability, only mildly affected patients without much potential for
398 recovery could be recruited. We attempted to navigate this problem by translating the leg MRI
399 protocol to one of the hospital's MRI scanners (Siemens Skyra Fit 3T; Siemens Healthineers,
400 Erlangen, Germany) to limit the need for participants to travel. This attempt, however, was
401 unsuccessful due to hardware limitations of the scanner relating to how lateral the spectroscopy
402 voxels can be placed. As a result of the limited available patient population, it would be difficult to
403 generalize the findings from this study alone to the broader stroke population including patients with
404 greater stroke severities and patients with haemorrhage.

405 Furthermore, despite our intention to keep the stroke onset to scan time narrow, there were
406 difficulties regarding availability of the research MRI scanner (for example, closure over holiday
407 periods, and competition with other studies) and a prohibitively slow pace of recruitment. For these
408 reasons, we had to expand this window to what we acknowledge is a wide period of time that may
409 limit the sensitivity of our analysis. As presented in Table 1, most of our participants were imaged
410 between 2-4 weeks after onset of symptoms.

411 The spectroscopy biomarkers provided further challenges in that in this patient population we were
412 unable to consistently resolve peaks for intra- and extra-myocellular lipid concentrations, which is a
413 technical limitation of the spectroscopy technique. Whilst the spectroscopy results were interesting,
414 these were only analysable on a subgroup ($N \leq 14$) of this small study.

415 These factors combined result in a study which is likely to be statistically underpowered and
416 therefore susceptible to under- or over-representing reported significant biomarker correlations.
417 Because of these statistical limitations, we did not attempt to correct for multiple correlations which
418 would have reduced the statistical significance of the correlations identified. However, we hope to

419 have highlighted some biomarkers of potential clinical interest for future research (including a novel
420 application of lower limb MRI biomarkers) in addition to identifying some key practical problems
421 that could be addressed in the design of further studies. Specifically, we would welcome future
422 studies which included a broader range of stroke severities, a larger sample size, and a narrower
423 window of stroke onset times and hope we have demonstrated some of the practical barriers that
424 would need to be overcome to enable such future research. Specifically, longitudinal observation of
425 changes in the IMCL/EMCL ratio following stroke would be helpful given the lack of available
426 literature and potentially relevant findings identified in our study. Further, motor recovery is
427 important but only one affected function for patients with stroke, and we would welcome future
428 research investigating MRI biomarkers which may reflect recovery potential for speech or cognitive
429 impairment too. As rehabilitation interventions for stroke grow in complexity, the need for
430 biomarkers to both predict and measure recovery will grow – interventional studies may also present
431 an opportunity to further MRI biomarker research in this field.

432 **5 Conclusion**

433 This study supports previous literature indicating a positive correlation between the integrity of the
434 corticospinal tract and motor recovery post-stroke, expanding the limited available literature
435 describing this relationship specifically for the lower limb. However, recovery of functional
436 ambulation behaved differently to other clinical recovery markers by demonstrating an inverse
437 relationship with corticospinal tract integrity.

438 We have also presented a novel protocol for the combined imaging of muscle biomarkers with brain
439 imaging in stroke patients. We have demonstrated that this is possible in prospective observational
440 research settings, although does have technical limitations; particularly in the application of
441 spectroscopy to assess microscopic fat distribution within muscles and transferability to all scanners
442 in common clinical use.

443 Our study was exploratory in nature and therefore not statistically powered to enable reliable
444 inferences; however, the correlations identified between both brain and leg MRI biomarkers and
445 markers of clinical lower limb recovery may be of potential interest for future research.

446 **6 Conflict of Interest**

447 *The authors declare that the research was conducted in the absence of any commercial or financial*
448 *relationships that could be construed as a potential conflict of interest.*

449 **7 Author Contributions**

450 Specific author contributions have been referenced throughout the manuscript. All authors (included
451 those not specifically referenced within the manuscript) contributed to the planning, conduct, and
452 interpretation of the study results.

453 **8 Funding**

454 This study was funded by a grant awarded to the senior author (DM) by the Newcastle Biomedical
455 Research Council.

456 **9 Acknowledgments**

457 We wish to acknowledge the efforts of all our study participants and their families. We also would
458 like to acknowledge the efforts of Mr. Philip English and Dr. Matt Birkbeck in exploring the use of
459 an in-hospital MRI scanner for this study.

460 **10 Bibliography**

- 461 1. King D, Wittenberg R, Patel A, Quayyum Z, Berdunov V, Knapp M. The future
462 incidence, prevalence and costs of stroke in the UK. *Age Ageing* [Internet]. 2020 Feb
463 27 [cited 2023 Feb 12];49(2):277–82. Available from:
464 <https://pubmed.ncbi.nlm.nih.gov/31957781/>
- 465 2. Physical effects of stroke | Stroke Association [Internet]. [cited 2023 May 25].
466 Available from: <https://www.stroke.org.uk/effects-of-stroke/physical-effects-of-stroke>
- 467 3. Wade DT, Hewer RL. Functional abilities after stroke: measurement, natural history
468 and prognosis. *J Neurol Neurosurg Psychiatry* [Internet]. 1987 Feb 1 [cited 2023 Feb
469 13];50(2):177–82. Available from: <https://jnnp.bmj.com/content/50/2/177>
- 470 4. Friedman PJ, Friedman PI. Gait recovery after hemiplegic stroke. *Disabil Rehabil*
471 [Internet]. 1990 [cited 2023 Feb 13];12(3):119–22. Available from:
472 <https://www.tandfonline.com/action/journalInformation?journalCode=idre20>
- 473 5. Smith MC, Barber PA, Stinear CM. The TWIST Algorithm Predicts Time to Walking
474 Independently After Stroke. *Neurorehabil Neural Repair* [Internet]. 2017 Oct 1 [cited
475 2023 Feb 12];31(10–11):955–64. Available from:
476 <https://europepmc.org/article/MED/29090654>
- 477 6. Grefkes C, Grefkes C, Fink GR, Fink GR. Recovery from stroke: Current concepts and
478 future perspectives. *Neurol Res Pract* [Internet]. 2020 Jun 16 [cited 2023 Sep
479 11];2(1):1–10. Available from:
480 <https://neurolrespract.biomedcentral.com/articles/10.1186/s42466-020-00060-6>
- 481 7. Kwakkel G, Kollen BJ, Van der Grond J V., Prevo AJH. Probability of regaining
482 dexterity in the flaccid upper limb: impact of severity of paresis and time since onset in
483 acute stroke. *Stroke* [Internet]. 2003 Sep 1 [cited 2023 Sep 11];34(9):2181–6. Available
484 from: <https://pubmed.ncbi.nlm.nih.gov/12907818/>
- 485 8. Smith MC, Barber AP, Scrivener BJ, Stinear CM. The TWIST Tool Predicts When
486 Patients Will Recover Independent Walking After Stroke: An Observational Study.
487 <https://doi.org/10.1177/15459683221085287> [Internet]. 2022 May 18 [cited 2023 Feb
488 13];36(7):461–71. Available from:
489 [https://journals.sagepub.com/doi/10.1177/15459683221085287?url_ver=Z39.88-
490 2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed](https://journals.sagepub.com/doi/10.1177/15459683221085287?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed)
- 491 9. Stinear CM, Ward NS. How useful is imaging in predicting outcomes in stroke
492 rehabilitation? *Int J Stroke* [Internet]. 2013 Jan [cited 2023 Feb 12];8(1):33–7.
493 Available from: <https://pubmed.ncbi.nlm.nih.gov/23280267/>

- 494 10. Heiss WD, Kidwell CS. Imaging for prediction of functional outcome and assessment
495 of recovery in ischemic stroke. *Stroke* [Internet]. 2014 [cited 2023 Feb 12];45(4):1195–
496 201. Available from: <https://pubmed.ncbi.nlm.nih.gov/24595589/>
- 497 11. Milot MH, Cramer SC. Biomarkers of recovery after stroke. *Curr Opin Neurol*
498 [Internet]. 2008 Dec [cited 2023 Feb 12];21(6):654–9. Available from:
499 <https://pubmed.ncbi.nlm.nih.gov/18989108/>
- 500 12. Stinear CM, Barber PA, Petoe M, Anwar S, Byblow WD. The PREP algorithm predicts
501 potential for upper limb recovery after stroke. *Brain* [Internet]. 2012 [cited 2023 Feb
502 12];135(Pt 8):2527–35. Available from: <https://pubmed.ncbi.nlm.nih.gov/22689909/>
- 503 13. Stinear CM. Prediction of motor recovery after stroke: advances in biomarkers. *Lancet*
504 *Neurol* [Internet]. 2017 Oct 1 [cited 2023 Feb 12];16(10):826–36. Available from:
505 <https://pubmed.ncbi.nlm.nih.gov/28920888/>
- 506 14. Boyd LA, Hayward KS, Ward NS, Stinear CM, Rosso C, Fisher RJ, et al. Biomarkers
507 of Stroke Recovery: Consensus-Based Core Recommendations from the Stroke
508 Recovery and Rehabilitation Roundtable. *Neurorehabil Neural Repair* [Internet]. 2017
509 Oct 1 [cited 2023 Feb 12];31(10–11):864–76. Available from:
510 <https://pubmed.ncbi.nlm.nih.gov/29233071/>
- 511 15. Buma FE, Lindeman E, Ramsey NF, Kwakkel G. Functional neuroimaging studies of
512 early upper limb recovery after stroke: a systematic review of the literature.
513 *Neurorehabil Neural Repair* [Internet]. 2010 Sep [cited 2023 Feb 12];24(7):589–608.
514 Available from: <https://pubmed.ncbi.nlm.nih.gov/20439501/>
- 515 16. Jin J fen, Guo Z ting, Zhang Y ping, Chen Y yuan. Prediction of motor recovery after
516 ischemic stroke using diffusion tensor imaging: A meta-analysis. *World J Emerg Med*
517 [Internet]. 2017 [cited 2023 Feb 12];8(2):99. Available from:
518 <https://pubmed.ncbi.nlm.nih.gov/28458752/>
- 519 17. Kalladka D, Muir K. DIFFUSION MR CORRELATES OF MOTOR FUNCTION
520 RECOVERY AFTER STROKE: A SYSTEMATIC REVIEW. *J Neurol Neurosurg*
521 *Psychiatry* [Internet]. 2013 Nov 1 [cited 2023 Feb 12];84(11):e2–e2. Available from:
522 <https://jnnp.bmj.com/content/84/11/e2.195>
- 523 18. Königsberg A, DeMarco AT, Mayer C, Wouters A, Schlemm E, Ebinger M, et al.
524 Influence of stroke infarct location on quality of life assessed in a multivariate lesion-
525 symptom mapping study. *Scientific Reports* 2021 11:1 [Internet]. 2021 Jun 29 [cited
526 2023 Sep 11];11(1):1–8. Available from: [https://www.nature.com/articles/s41598-021-
527 92865-x](https://www.nature.com/articles/s41598-021-92865-x)
- 528 19. Jang SH, Choi BY, Chang CH, Kim SH, Chang MC. Prediction of motor outcome
529 based on diffusion tensor tractography findings in thalamic hemorrhage. *International*
530 *Journal of Neuroscience*. 2013 Apr;123(4):233–9.
- 531 20. Cho SH, Kim SH, Choi BY, Cho SH, Kang JH, Lee CH, et al. Motor outcome
532 according to diffusion tensor tractography findings in the early stage of intracerebral
533 hemorrhage. *Neurosci Lett*. 2007 Jun 27;421(2):142–6.

- 534 21. Kim BR, Moon WJ, Kim H, Jung E, Lee J. Transcranial Magnetic Stimulation and
535 Diffusion Tensor Tractography for Evaluating Ambulation after Stroke. *J Stroke*
536 [Internet]. 2016 May 1 [cited 2023 Feb 13];18(2):220–6. Available from:
537 <http://www.ncbi.nlm.nih.gov/pubmed/27283282>
- 538 22. Cho SH, Kim DG, Kim DS, Kim YH, Lee CH, Jang SH. Motor outcome according to
539 the integrity of the corticospinal tract determined by diffusion tensor tractography in the
540 early stage of corona radiata infarct. *Neurosci Lett*. 2007 Oct 16;426(2):123–7.
- 541 23. Promsri A, Haid T, Werner I, Federolf P. Leg Dominance Effects on Postural Control
542 When Performing Challenging Balance Exercises. *Brain Sci* [Internet]. 2020 Mar 1
543 [cited 2023 Sep 12];10(3). Available from: </pmc/articles/PMC7139434/>
- 544 24. Hernández ED, Forero SM, Galeano CP, Barbosa NE, Sunnerhagen KS, Alt Murphy M.
545 Intra- and inter-rater reliability of Fugl-Meyer Assessment of Lower Extremity early
546 after stroke. *Braz J Phys Ther* [Internet]. 2021 Nov 1 [cited 2023 May 26];25(6):709.
547 Available from: </pmc/articles/PMC8721065/>
- 548 25. Bushnell C, Bettger JP, Cockroft KM, Cramer SC, Edelen MO, Hanley D, et al.
549 Chronic Stroke Outcome Measures for Motor Function Intervention Trials: Expert
550 Panel Recommendations. *Circ Cardiovasc Qual Outcomes* [Internet]. 2015 Oct 1 [cited
551 2023 May 26];8(6 Suppl 3):S163–9. Available from:
552 <https://pubmed.ncbi.nlm.nih.gov/26515205/>
- 553 26. Kwakkel G, Lannin NA, Borschmann K, English C, Ali M, Churilov L, et al.
554 Standardized measurement of sensorimotor recovery in stroke trials: Consensus-based
555 core recommendations from the Stroke Recovery and Rehabilitation Roundtable. *Int J*
556 *Stroke* [Internet]. 2017 Jul 1 [cited 2023 May 26];12(5):451–61. Available from:
557 <https://pubmed.ncbi.nlm.nih.gov/28697709/>
- 558 27. Wityk RJ, Pessin MS, Kaplan RF, Caplan LR. Serial assessment of acute stroke using
559 the NIH Stroke Scale. *Stroke* [Internet]. 1994 [cited 2023 May 26];25(2):362–5.
560 Available from: <https://www.ahajournals.org/doi/abs/10.1161/01.STR.25.2.362>
- 561 28. Bandinelli S, Benvenuti E, Del Lungo I, Baccini M, Benvenuti F, Di Iorio A, et al.
562 Measuring muscular strength of the lower limbs by hand-held dynamometer: a standard
563 protocol. *Aging (Milano)* [Internet]. 1999 [cited 2023 May 26];11(5):287–93. Available
564 from: <https://pubmed.ncbi.nlm.nih.gov/10631877/>
- 565 29. Mehrholz J, Wagner K, Rutte K, Meißner D, Pohl M. Predictive validity and
566 responsiveness of the functional ambulation category in hemiparetic patients after
567 stroke. *Arch Phys Med Rehabil* [Internet]. 2007 Oct [cited 2023 May 26];88(10):1314–
568 9. Available from: <https://pubmed.ncbi.nlm.nih.gov/17908575/>
- 569 30. Moura LM, Luccas R, De Paiva JPQ, Amaro E, Leemans A, Leite C da C, et al.
570 Diffusion tensor imaging biomarkers to predict motor outcomes in stroke: A narrative
571 review. *Front Neurol*. 2019 May 8;10(MAY):444825.

- 572 31. Winklewski PJ, Sabisz A, Naumczyk P, Jodzio K, Szurowska E, Szarmach A.
573 Understanding the physiopathology behind axial and radial diffusivity changes-what do
574 we Know? *Front Neurol*. 2018 Feb 27;9(FEB):336887.
- 575 32. MERCURI E, CINI C, COUNSELL S, ALLSOP J, ZOLKIPLI Z, JUNGBLUTH H, et
576 al. Muscle MRI findings in a three-generation family affected by Bethlem myopathy.
577 *European Journal of Paediatric Neurology*. 2002 Nov;6(6):309–14.
- 578 33. Finlayson S, Morrow JM, Rodriguez Cruz PM, Sinclair CDJ, Fischmann A, Thornton
579 JS, et al. Muscle magnetic resonance imaging in congenital myasthenic syndromes.
580 *Muscle Nerve*. 2016 Aug 1;54(2):211–9.
- 581 34. Grimm A, Meyer H, Nickel MD, Nittka M, Raithel E, Chaudry O, et al. Evaluation of
582 2-point, 3-point, and 6-point Dixon magnetic resonance imaging with flexible echo
583 timing for muscle fat quantification. *Eur J Radiol* [Internet]. 2018 Jun 1 [cited 2023 Feb
584 13];103:57–64. Available from: <https://pubmed.ncbi.nlm.nih.gov/29803386/>
- 585 35. MacHann J, Horstmann A, Born M, Hesse S, Hirsch FW. Diagnostic imaging in
586 obesity. *Best Pract Res Clin Endocrinol Metab* [Internet]. 2013 Apr [cited 2023 Sep
587 11];27(2):261–77. Available from: <https://pubmed.ncbi.nlm.nih.gov/23731887/>
- 588 36. Buonocore MH, Maddock RJ. Magnetic resonance spectroscopy of the brain: A review
589 of physical principles and technical methods. *Rev Neurosci* [Internet]. 2015 Dec 1
590 [cited 2023 Sep 11];26(6):609–32. Available from:
591 <https://www.degruyter.com/document/doi/10.1515/revneuro-2015-0010/html?lang=en>
- 592 37. Brennan NA, Fishbein KW, Reiter DA, Ferrucci L, Spencer RG. Contribution of
593 Intramyocellular Lipids to Decreased Computed Tomography Muscle Density With
594 Age. *Front Physiol*. 2021 Jun 30;12:632642.
- 595 38. Catani Marco, Thiebaut de Schotten Michel. Atlas of human brain connections. 2012
596 [cited 2023 Feb 13];519. Available from:
597 [https://books.google.com/books/about/Atlas_of_Human_Brain_Connections.html?id=n](https://books.google.com/books/about/Atlas_of_Human_Brain_Connections.html?id=nROILZ9HwEgC)
598 [ROILZ9HwEgC](https://books.google.com/books/about/Atlas_of_Human_Brain_Connections.html?id=nROILZ9HwEgC)
- 599 39. Yeh FC. Shape analysis of the human association pathways. *Neuroimage*. 2020 Dec
600 1;223:117329.
- 601 40. Yeh FC, Panesar S, Barrios J, Fernandes D, Abhinav K, Meola A, et al. Automatic
602 Removal of False Connections in Diffusion MRI Tractography Using Topology-
603 Informed Pruning (TIP). *Neurotherapeutics* [Internet]. 2019 Jan 15 [cited 2023 Feb
604 13];16(1):52. Available from: [/pmc/articles/PMC6361061/](https://pubmed.ncbi.nlm.nih.gov/31661061/)
- 605 41. Yeh FC, Verstynen TD, Wang Y, Fernández-Miranda JC, Tseng WY. Deterministic
606 Diffusion Fiber Tracking Improved by Quantitative Anisotropy. *PLoS One* [Internet].
607 2013 [cited 2023 Feb 13];8(11):80713. Available from: www.plosone.org
- 608 42. Yeh FC, Panesar S, Fernandes D, Meola A, Yoshino M, Fernandez-Miranda JC, et al.
609 Population-averaged atlas of the macroscale human structural connectome and its
610 network topology. *Neuroimage*. 2018 Sep 1;178:57–68.

- 611 43. Guertin PA. Central pattern generator for locomotion: Anatomical, physiological, and
612 pathophysiological considerations. *Front Neurol*. 2013 Feb 8;3 FEB:183.
- 613 44. Jang SH, Chang CH, Lee J, Kim CS, Seo JP, Yeo SS. Functional role of the
614 corticoreticular pathway in chronic stroke patients. *Stroke* [Internet]. 2013 Apr [cited
615 2023 Feb 13];44(4):1099–104. Available from:
616 <https://pubmed.ncbi.nlm.nih.gov/23444306/>
- 617 45. Kortebein P, Ferrando A, Lombeida J, Wolfe R, Evans WJ. Effect of 10 Days of Bed
618 Rest on Skeletal Muscle in Healthy Older Adults. *JAMA* [Internet]. 2007 Apr 25 [cited
619 2023 Feb 13];297(16):1769–74. Available from:
620 <https://jamanetwork.com/journals/jama/fullarticle/206740>
- 621 46. Gonzales RG, Gonzales AG, Ramos M. Meta-Analysis of Acute Sarcopenia among
622 Hospitalized Elderly Patients. *J Geriatr Med Gerontol*. 2021 Oct 22;7(4):126.
- 623 47. Naritomi H, Moriwaki H, Metoki N, Nishimura H, Higashi Y, Yamamoto Y, et al.
624 Effects of edaravone on muscle atrophy and locomotor function in patients with
625 ischemic stroke: A randomized controlled pilot study. *Drugs in R and D* [Internet]. 2010
626 Nov 27 [cited 2023 Feb 13];10(3):155–63. Available from:
627 <https://link.springer.com/article/10.2165/11586550-000000000-00000>
- 628 48. Schrauwen-Hinderling VB, Hesselink MKC, Schrauwen P, Kooi ME. Intramyocellular
629 lipid content in human skeletal muscle. *Obesity (Silver Spring)* [Internet]. 2006 Mar
630 [cited 2023 Feb 13];14(3):357–67. Available from:
631 <https://pubmed.ncbi.nlm.nih.gov/16648604/>
- 632 49. Arasaki K, Igarashi O, Ichikawa Y, Machida T, Shirozu I, Hyodo A, et al. Reduction in
633 the motor unit number estimate (MUNE) after cerebral infarction. *J Neurol Sci*. 2006
634 Dec 1;250(1–2):27–32.
- 635 50. Kortebein P, Ferrando A, Lombeida J, Wolfe R, Evans WJ. Effect of 10 days of bed rest
636 on skeletal muscle in healthy older adults [8]. *JAMA*. 2007 Apr 25;297(16):1772–4.
- 637 51. Li W, Yue T, Liu Y. New understanding of the pathogenesis and treatment of stroke-
638 related sarcopenia. *Biomedicine & Pharmacotherapy*. 2020 Nov 1;131:110721.

639

640

641

642 **11 Figure legends**

643 Figure 1: Consent and data collection procedures.

644 Figure 2: 3-point Dixon mid-thigh MRI data with reconstructed fat (top) and water (bottom) maps.
645 The vastus lateralis muscle is highlighted on the bottom right.

646 Figure 3: Example placement of a spectroscopy voxel (orange box) within the right vastus lateralis
647 muscle.

648 Figure 4: Quantification process for extracting intra- and extra-myocellular lipid concentrations from
649 acquired proton spectroscopy. Original: Raw spectroscopy data. Estimate: A model fitted to the
650 generated data. Individual components: Individual peaks can be de-convolved to separate from each
651 other (3 – IMCL, 4 – EMCL). Residue: Represents the deviation from the raw data.

652 Figure 5: Colour fractional anisotropy maps used to segment cerebral peduncles (left), posterior limb
653 of internal capsule (middle), and centrum semiovale (right) regions.

654 Figure 6: Coronal view of automatically reconstructed corticospinal tracts, rendered in 3D.

655 Figure 7: Attrition flowchart.

656 **12 Tables**

657 Table 1: Individual demographic and baseline clinical data.

	Gender	Age (years)	Affected leg	Dominant leg	Infarct location	Lower Limb Motor NIHSS	Lower Limb MRC Power	Baseline Functional Ambulation Category	Baseline Lower Limb Fugl-Meyer
BA1	Male	63	Right	Right	Basal Ganglia	2	4	2	29
BC2	Male	53	Right	Right	Frontal	1	4	5	31
BC3	Female	61	Left	Right	-	1	4	5	32
BC4	Female	81	Right	Right	Brainstem	2	4	2	26
BC5	Female	60	Right	Right	Basal Ganglia	1	1	5	33
AA2	Male	62	Left	Right	Parietal	2	5	2	21
AA3	Male	43	Left	Left	Frontal	1	4	5	33
AA5	Female	77	Left	Right	Frontal	1	4	3	34
BA5	Male	48	Left	Left	Parietal	1	3	2	28
AA7	Male	67	Left	Right	Frontal	1	5	5	34
AA9	Male	54	Right	Right	Frontal	1	2	2	20
AA12	Female	66	Left	Right	Brainstem	1	4	4	32
AA14	Male	64	Right	Right	Basal Ganglia	1	5	5	30
AA16	Female	55	Right	Right	Parietal	1	4	5	29
AA17	Male	79	Left	Right	Brainstem	0	4	5	31
BC8	Male	59	Right	Right	Parietal	1	4	4	34
BC9	Male	49	Right	Right	Brainstem	1	4	5	32
BC10	Male	59	Left	Right	Frontal	1	4	5	34
BA6	Male	68	Right	Right	Basal Ganglia	1	4	5	32
BC14	Male	78	Left	Right	Frontal	0	4	5	33
BA7	Male	80	Left	Right	Brainstem	1	4	3	31
AA21	Male	57	Right	Right	Frontal	1	4	5	33
AA22	Male	48	Left	Right	Basal Ganglia	2	4	5	33
BC16	Female	82	Right	Right	Brainstem	2	4	5	33
BC17	Female	71	Left	Right	Basal Ganglia	2	0	4	25
AA24	Female	84	Left	Right	Brainstem	0	4	4	32
AA26	Male	42	Right	Right	Temporal	1	4	5	32
AA28	Male	62	Left	Right	No infarct	1	4	5	33

658

659

660 Table 2: Per participant brain biomarker results, reported separately for the unaffected (left) and
 661 affected (right) hemispheres.

	Unaffected Hemisphere					Affected Hemisphere				
	Cerebral Peduncle FA	Posterior limb of internal capsule FA	Centrum Semioval e FA	Whole corticospinal tract FA	Whole corticospinal tract volume (mm ³)	Cerebral Peduncle FA	Posterior limb of internal capsule FA	Centrum Semioval e FA	Whole corticospinal tract FA	Whole corticospinal tract volume (mm ³)
BA1	0.69	0.63	0.43	0.53	15874.5	0.64	0.49	0.29	0.39	14141.7
BC2	0.66	0.64	0.33	0.5	19252.2	0.69	0.67	0.34	0.53	8213.56
BC3	-	-	-	-	-	-	-	-	-	-
BC4	0.62	0.6	0.28	0.47	16470.5	0.65	0.62	0.32	0.44	18571.7
BC5	0.62	0.58	0.29	0.49	11586.5	0.67	0.61	0.33	0.5	17566.3
AA2	0.74	0.69	0.43	0.55	20450	0.59	0.56	0.39	0.46	9958.11
AA3	-	-	-	-	-	-	-	-	-	-
AA5	0.69	0.68	0.59	0.55	14106.5	0.54	0.45	0.57	0.49	9461.84
BA5	0.75	0.71	0.34	0.52	20234.2	0.63	0.53	0.36	0.45	20927.5
AA7	0.76	0.7	0.42	0.6	9031.28	0.57	0.53	0.37	0.51	18567
AA9	0.6	0.6	0.32	0.51	7708.9	0.66	0.66	0.35	0.47	2939.2
AA12	0.73	0.6	0.39	0.47	6535.11	0.7	0.55	0.36	0.43	2594.88
AA14	0.71	0.53	0.26	0.42	7272.28	0.59	0.48	0.36	0.43	10055.3
AA16	-	-	-	-	-	-	-	-	-	-
AA17	0.68	0.6	0.31	0.51	13366.2	0.58	0.61	0.28	0.48	7752.49
BC8	0.63	0.48	0.31	0.4	8238.2	0.66	0.55	0.28	0.41	8634.74
BC9	0.71	0.71	0.38	0.47	10026.2	0.74	0.72	0.4	0.49	16343.8
BC10	0.58	0.62	0.45	0.5	14369.3	0.4	0.41	0.32	0.37	12118
BA6	0.59	0.53	0.33	0.46	6565.22	0.65	0.64	0.31	0.52	6615.66
BC14	0.62	0.6	0.4	0.5	11897.4	0.71	0.64	0.36	0.51	15708
BA7	0.7	0.64	0.37	0.49	24362.6	0.69	0.59	0.29	0.45	26798.2
AA21	0.73	0.66	0.31	0.49	15452.2	0.73	0.64	0.3	0.45	17330.5
AA22	0.76	0.67	0.34	0.52	16295.7	0.66	0.5	0.29	0.48	7168.24
BC16	0.6	0.59	0.29	0.5	16958.6	0.59	0.59	0.28	0.46	15395.9
BC17	0.67	0.7	0.35	0.52	20164.9	0.61	0.57	0.29	0.45	15587.1
AA24	0.74	0.63	0.41	0.51	17925.7	0.61	0.55	0.35	0.48	13409.9
AA26	0.63	0.67	0.36	0.46	20349.1	0.66	0.72	0.36	0.49	19254.5
Mean	0.67542	0.6275	0.3620833	0.4975	14353.89	0.634167	0.578333	0.339583	0.464167	13129.76
Std D	0.05737	0.059178	0.0700583	0.040748	5050.671	0.070411	0.078138	0.059964	0.039149	5813.014

662

663